Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Ustekinumab Drug Levels in Maternal and Cord Blood in a Woman With Crohn's Disease Treated Until 33 Weeks of Gestation.

Rowan CR, Cullen G, Mulcahy HE, Keegan D, Byrne K, Murphy DJ, Sheridan J, Doherty GA.

J Crohns Colitis. 2018 Feb 28;12(3):376-378. doi: 10.1093/ecco-jcc/jjx141.

PMID:
29045603
2.

Drug Levels in the Maternal Serum, Cord Blood and Breast Milk of a Ustekinumab-Treated Patient with Crohn's Disease.

Klenske E, Osaba L, Nagore D, Rath T, Neurath MF, Atreya R.

J Crohns Colitis. 2019 Feb 1;13(2):267-269. doi: 10.1093/ecco-jcc/jjy153.

PMID:
30388211
3.

Ustekinumab therapy for Crohn's disease during pregnancy: a case report and review of the literature.

Cortes X, Borrás-Blasco J, Antequera B, Fernandez-Martinez S, Casterá E, Martin S, Molés JR.

J Clin Pharm Ther. 2017 Apr;42(2):234-236. doi: 10.1111/jcpt.12492. Epub 2016 Dec 22. Review.

PMID:
28004853
4.

Successful pregnancy outcome under prolonged ustekinumab treatment in a patient with Crohn's disease and paradoxical psoriasis.

Galli-Novak E, Mook SC, Büning J, Schmidt E, Zillikens D, Thaci D, Ludwig RJ.

J Eur Acad Dermatol Venereol. 2016 Dec;30(12):e191-e192. doi: 10.1111/jdv.13499. Epub 2015 Nov 11. No abstract available.

PMID:
26559393
5.

Normal pregnancy in a woman with nesidioblastosis treated with somatostatin analog octreotide.

Boulanger C, Vezzosi D, Bennet A, Lorenzini F, Fauvel J, Caron P.

J Endocrinol Invest. 2004 May;27(5):465-70.

PMID:
15279081
6.

Ustekinumab as Effective Treatment for Refractory Amicrobial Pustulosis of the Folds Associated with Crohn's Disease.

Al-Raddadi R, Frances C, Moguelet P, Bachmeyer C, Guégan S.

Acta Derm Venereol. 2017 Mar 10;97(3):389-390. doi: 10.2340/00015555-2544. No abstract available.

7.

Efficacy of Combination Vedolizumab and Ustekinumab for Refractory Crohn's Disease.

Huff-Hardy K, Bedair M, Vazquez R, Burstein E.

Inflamm Bowel Dis. 2017 Oct;23(10):E49. doi: 10.1097/MIB.0000000000001232. No abstract available.

PMID:
28858074
8.

Fetal death in utero and miscarriage in a patient with Crohn's disease under therapy with ustekinumab: case-report and review of the literature.

Venturin C, Nancey S, Danion P, Uzzan M, Chauvenet M, Bergoin C, Roblin X, Flourié B, Boschetti G.

BMC Gastroenterol. 2017 Jun 19;17(1):80. doi: 10.1186/s12876-017-0633-6. Review.

9.

Safe use of infliximab for the treatment of fistulizing Crohn's disease during pregnancy within 3 months of conception.

Angelucci E, Cocco A, Viscido A, Caprilli R.

Inflamm Bowel Dis. 2008 Mar;14(3):435-6. No abstract available.

PMID:
18050300
10.

[Infliximab in the treatment of Crohn's disease -- a practical approach. Infliximab and chronic Crohn's disease--Consensus statement of the Working Group on Chronic Inflammatory Crohn's Diseases of the OGGH].

Tilg H, Knoflach P, Petritsch W, Vogelsang H, Reinisch W; Working Group on Chronic Inflammatory Crohn's Diseases of the OGGH.

Z Gastroenterol. 2004 Oct;42(10):1256-63. Review. German. No abstract available.

PMID:
15508068
11.

Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease.

Mahadevan U, Kane S, Sandborn WJ, Cohen RD, Hanson K, Terdiman JP, Binion DG.

Aliment Pharmacol Ther. 2005 Mar 15;21(6):733-8. Review.

12.

Ustekinumab for the treatment of Crohn's disease.

Hansen T, Targownik LE.

Expert Rev Gastroenterol Hepatol. 2016 Sep;10(9):989-94. doi: 10.1080/17474124.2016.1215912. Epub 2016 Jul 28. Review.

PMID:
27450626
13.

Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease.

Battat R, Kopylov U, Bessissow T, Bitton A, Cohen A, Jain A, Martel M, Seidman E, Afif W.

Clin Gastroenterol Hepatol. 2017 Sep;15(9):1427-1434.e2. doi: 10.1016/j.cgh.2017.03.032. Epub 2017 Mar 29.

PMID:
28365485
14.

Ustekinumab to treat Crohn's disease.

Gisbert JP, Chaparro M.

Gastroenterol Hepatol. 2017 Dec;40(10):688-698. doi: 10.1016/j.gastrohep.2017.08.006. Epub 2017 Oct 16. Review. English, Spanish.

PMID:
29042094
15.

Treatment of Crohn's disease in pregnant women: drug and multidisciplinary approaches.

Cury DB, Moss AC.

World J Gastroenterol. 2014 Jul 21;20(27):8790-5. doi: 10.3748/wjg.v20.i27.8790. Review.

16.

Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease.

Adedokun OJ, Xu Z, Gasink C, Jacobstein D, Szapary P, Johanns J, Gao LL, Davis HM, Hanauer SB, Feagan BG, Ghosh S, Sandborn WJ.

Gastroenterology. 2018 May;154(6):1660-1671. doi: 10.1053/j.gastro.2018.01.043. Epub 2018 Feb 1.

17.

Circulating Interleukin 6 and Albumin, and Infliximab Levels Are Good Predictors of Recovering Efficacy After Dose Escalation Infliximab Therapy in Patients with Loss of Response to Treatment for Crohn's Disease: A Prospective Clinical Trial.

Suzuki Y, Matsui T, Ito H, Ashida T, Nakamura S, Motoya S, Matsumoto T, Sato N, Ozaki K, Watanabe M, Hibi T.

Inflamm Bowel Dis. 2015 Sep;21(9):2114-22. doi: 10.1097/MIB.0000000000000475.

PMID:
26218144
18.

Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease.

Yacyshyn BR, Barish C, Goff J, Dalke D, Gaspari M, Yu R, Tami J, Dorr FA, Sewell KL.

Aliment Pharmacol Ther. 2002 Oct;16(10):1761-70.

19.

Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?

Domènech E, Hinojosa J, Nos P, Garcia-Planella E, Cabré E, Bernal I, Gassull MA.

Aliment Pharmacol Ther. 2005 Dec;22(11-12):1107-13.

20.

Pregnancy and Crohn's disease.

Mottet C, Juillerat P, Gonvers JJ, Froehlich F, Burnand B, Vader JP, Michetti P, Felley C.

Digestion. 2005;71(1):54-61. Epub 2005 Feb 4. Review.

PMID:
15711051

Supplemental Content

Support Center